Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 11;5(11):1052-1058.
doi: 10.1002/bco2.418. eCollection 2024 Nov.

Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

Ekamjit S Deol  1 , Reza Nabavizadeh  1 , Roxane R Lavoie  1 , Mihai G Dumbrava  2 , Edlira Horjeti  1 , Prabin Thapa  1 , John C Cheville  2   3 , Igor Frank  1 , Fabrice Lucien  1
Affiliations

Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer

Ekamjit S Deol et al. BJUI Compass. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] BJUI Compass. 2024 Dec 30;5(12):1324-1329. doi: 10.1002/bco2.482. eCollection 2024 Dec. BJUI Compass. 2024. PMID: 39744071 Free PMC article.

Abstract

Background: Neoadjuvant platinum-based chemotherapy offers a modest survival advantage in muscle-invasive bladder cancer (MIBC) for patients with pathologic response. B7-H3 (CD276), an immune checkpoint overexpressed in various cancers, including urothelial-cell carcinoma (UCC), has been associated with chemoresistance and poor oncologic outcomes. We aimed to explore if B7H3 expression on bladder biopsy samples was a predictive biomarker for pathologic response to neoadjuvant platinum-based chemotherapy.

Methods: This was a retrospective cohort study among MIBC patients receiving neoadjuvant platinum-based chemotherapy followed by radical cystectomy. All patients underwent routine preoperative biopsy of their tumour. Immunohistochemistry was used to evaluate B7-H3 expression from pre-operative specimens. The primary outcome of interest was pathologic complete response (pCR). Statistical analysis included Mann-Whitney U test, Fisher's exact test, Kaplan-Meier method, and Cox regression for survival analysis.

Results: Among 87 patients analysed, high B7-H3 expression was found in 44.8% (n = 39) of patients. The median follow-up periods were similar between the high and low B7-H3 groups (high expression; 4.29 years [SD 3.04], low expression 3.94 years [SD 3.04], p = 0.60). Only 20.5% of patients with high B7-H3 expression achieved pCR, compared to 41.7% in the low expression group (p = 0.04). Cox regression showed no significant differences in recurrence-free or cancer-specific survival between the high and low B7-H3 expression groups (p > 0.05).

Conclusion: High B7-H3 expression is associated with a reduced likelihood of achieving pCR in MIBC patients undergoing neoadjuvant chemotherapy. This suggests B7-H3's potential as a predictive biomarker for chemotherapy response. Further research is needed to explore the role of B7-H3 on platinum-based chemotherapy response in urothelial cancer.

Keywords: biomarkers; bladder cancer; cystectomy; neoadjuvant chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier curves of event any recurrence with patients grouped either into pathologic complete response or not complete pathologic complete response.
FIGURE 2
FIGURE 2
Kaplan–Meier curves of event any recurrence with patients grouped either into low B7H3 expression or high B7H3 expression.
See this image and copyright information in PMC

References

    1. Vetterlein MW, Wankowicz SA, Seisen T, Lander R, Löppenberg B, Chun FKH, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology. Cancer. 2017;123(22):4346–4355. 10.1002/cncr.30907 - DOI - PubMed
    1. Vale C. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta‐analysis. Lancet. 2003;361(9373):1927–1934. 10.1016/S0140-6736(03)13580-5 - DOI - PubMed
    1. Grossman HB, Natale RB, Tangen CM, Speights V, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–866. 10.1056/NEJMoa022148 - DOI - PubMed
    1. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta‐analysis. Eur Urol. 2014;65(2):350–357. 10.1016/j.eururo.2013.06.049 - DOI - PubMed
    1. Sonpavde G, Goldman BH, Speights V, Lerner SP, Wood DP, Vogelzang NJ, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–4109. 10.1002/cncr.24466 - DOI - PMC - PubMed

LinkOut - more resources